statistiche ricercatore

VISCA, DINA

Distribuzione geografica

Continente	#
NA - Nord America	8.318
EU - Europa	3.170
AS - Asia	2.991
SA - Sud America	400
Continente sconosciuto - Info sul continente non disponibili	361
AF - Africa	87
OC - Oceania	13
Totale	15.340

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	8.130
IT - Italia	1.698
SG - Singapore	1.105
CN - Cina	613
HK - Hong Kong	438
VN - Vietnam	407
BR - Brasile	318
UA - Ucraina	286
IE - Irlanda	197
DE - Germania	179
GB - Regno Unito	168
SE - Svezia	156
BD - Bangladesh	140
FR - Francia	137
RU - Federazione Russa	107
CA - Canada	81
TR - Turchia	81
FI - Finlandia	65
MX - Messico	60
AT - Austria	49
JP - Giappone	36
AR - Argentina	35
IN - India	31
NG - Nigeria	27
ZA - Sudafrica	24
ES - Italia	23
ID - Indonesia	23
IQ - Iraq	23
NL - Olanda	22
PL - Polonia	18
CL - Cile	14
PK - Pakistan	14
MY - Malesia	13
AU - Australia	12
CZ - Repubblica Ceca	12
LT - Lituania	9
PH - Filippine	9
SA - Arabia Saudita	9
TT - Trinidad e Tobago	9
CO - Colombia	7
IR - Iran	7
RO - Romania	7
VE - Venezuela	7
CR - Costa Rica	6
EC - Ecuador	6
JM - Giamaica	6
AE - Emirati Arabi Uniti	5
EG - Egitto	5
EU - Europa	5
HN - Honduras	5
HU - Ungheria	5
SK - Slovacchia (Repubblica Slovacca)	5
BE - Belgio	4
GT - Guatemala	4
JO - Giordania	4
KE - Kenya	4
KZ - Kazakistan	4
MA - Marocco	4
MD - Moldavia	4
NP - Nepal	4
OM - Oman	4
PT - Portogallo	4
PY - Paraguay	4
TN - Tunisia	4
UY - Uruguay	4
AL - Albania	3
DZ - Algeria	3
EE - Estonia	3
NI - Nicaragua	3
PE - Perù	3
SN - Senegal	3
SV - El Salvador	3
UZ - Uzbekistan	3
AZ - Azerbaigian	2
BB - Barbados	2
BH - Bahrain	2
BO - Bolivia	2
CH - Svizzera	2
DK - Danimarca	2
GN - Guinea	2
KH - Cambogia	2
KN - Saint Kitts e Nevis	2
LK - Sri Lanka	2
PR - Porto Rico	2
TH - Thailandia	2
ZM - Zambia	2
A2 - ???statistics.table.value.countryCode.A2???	1
AM - Armenia	1
BN - Brunei Darussalam	1
BS - Bahamas	1
BY - Bielorussia	1
CI - Costa d'Avorio	1
CU - Cuba	1
CY - Cipro	1
ET - Etiopia	1
GA - Gabon	1
GD - Grenada	1
GE - Georgia	1
GR - Grecia	1
IL - Israele	1
Totale	14.970

Salva come PNG Salva come JPEG

Città	#
Milan	1.051
Ashburn	831
San Jose	771
Fairfield	746
Singapore	590
Hong Kong	432
Council Bluffs	397
Woodbridge	352
Chandler	337
Houston	312
Seattle	288
Wilmington	286
Cambridge	279
Jacksonville	272
Dallas	214
Beijing	198
Dublin	190
Princeton	184
The Dalles	164
Ann Arbor	134
New York	132
Chicago	131
Boardman	124
Lauterbourg	112
Los Angeles	111
Rome	107
Nyköping	99
Santa Clara	97
Dearborn	94
Dong Ket	89
Ho Chi Minh City	89
San Diego	78
London	68
Izmir	62
Hanoi	51
Helsinki	51
Phoenix	47
Ogden	45
Munich	44
Mexico City	43
São Paulo	42
San Francisco	31
Nuremberg	30
Vienna	30
Atlanta	28
Abuja	27
Orem	27
Washington	27
Salt Lake City	26
Tokyo	26
Naples	25
Toronto	24
Frankfurt am Main	22
Redmond	21
Montreal	19
North Bergen	19
San Genesio Ed Uniti	19
Buffalo	18
Brooklyn	17
Como	17
Tampa	16
Guangzhou	15
Norwalk	15
Shanghai	15
Warsaw	15
Elk Grove Village	13
Haiphong	13
Hangzhou	13
Catania	12
Denver	12
Hefei	12
Belo Horizonte	11
Brno	11
Chennai	11
Johannesburg	11
Kunming	11
Miami	11
Varese	11
Baghdad	10
Columbus	9
Dhaka	9
Lancaster	9
Pavia	9
Stockholm	9
Bari	8
Boston	8
Brasília	8
Cedar Knolls	8
Charlotte	8
Florence	8
Jakarta	8
Kilburn	8
Kuala Lumpur	8
Magnago	8
Manchester	8
Memphis	8
Monza	8
Rio de Janeiro	8
Amsterdam	7
Biên Hòa	7
Totale	10.606

Salva come PNG Salva come JPEG

Nome	#
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases	335
Adverse Reactions to Food: Allergies and Intolerances	290
Classifying new anti-tuberculosis drugs: rationale and future perspectives	261
Adherence to Continuous Positive Airway Pressure in patients with Obstructive Sleep Apnoea. A ten year real life study	236
Airway inflammatory phenotypes: Making sputum cell evaluation more accessible for clinical use	217
Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis	208
When kidneys and lungs suffer together	206
Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae	200
Tuberculosis elimination: Where are we now?	193
Intestine: Organ or Apparatus?	186
Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial	185
Cardiovascular function in pulmonary emphysema	184
Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial	180
Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients	180
Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.	179
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases	178
Is bronchodilator the correct treatment for COPD subjects before EBUS?	177
Classification of Malabsorption Syndromes	173
Ambulatory oxygen in interstitial lung disease	171
Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler	171
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD	169
Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery	167
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis	165
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study	165
Ventilatory response to carbon dioxide output in subjects with congestive heart failure and in patients with COPD with comparable exercise capacity	160
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: A systematic review	159
Relationship between diabetes and respiratory diseases—Clinical and therapeutic aspects	159
Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns	157
Fecal calprotectin concentrations in alcoholic patients: A longitudinal study	156
Care-Related intervention in Rehabilitative Pneumology: Pulmonary Rehabilitation in Chronic Obstructive Broncopneumopathies (COPD) can benefit from a multidisciplinary approach? [Cure correlate in Pneumologia Riabilitativa: La Riabilitazione Polmonare nelle Broncopneumopatie Croniche Ostruttive (BPCO) può trarre beneficio da un approccio multidisciplinare?]	155
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis	153
World TB Day 2017: Strengthening the fight against TB	149
Electrocardiographic features of patients with COVID-19 pneumonia	149
The 5-repetition sit-to-stand test as an outcome measure for pulmonary rehabilitation in subjects with asthma	149
Minimal clinically important difference of the 6-min walking test in patients with asthma	148
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries	147
Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico	147
Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night	146
Evolution of programmatic definitions used intuberculosis prevention and care	145
Is Two Better Than One? The Impact of Doubling Training Volume in Severe COPD: A Randomized Controlled Study	145
Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine	145
Multi and extensively drug-resistant pulmonary tuberculosis: Advances in diagnosis and management	139
Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients	139
A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries	138
Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study	134
Pulmonary Rehabilitation and Asthma	133
Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts	130
The role of blood gas analysis in the post-acute phase of COVID-19 pneumonia	130
Combined use of electrocardiography and ultrasound to detect cardiac and pulmonary involvement after recovery from COVID-19 pneumonia: A case series	129
Brazilian Thoracic Association recommendations for the management of post-tuberculosis lung disease	127
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy	127
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network	126
Analysis of Patients with Asthma and Mixed Granulocytic Inflammatory Pattern in Sputum	124
Chronic cough in adults	124
Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations	122
Effectiveness of a Pulmonary Rehabilitation Program on Persistent Asthma Stratified for Severity	121
Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Authors' reply	120
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment	119
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact	114
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report	113
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression	112
Severity of COVID-19: The importance of being hypertensive	111
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease	111
Something is changing in adherence to CPAP therapy: Real world data after 1 year of treatment in patients with obstructive sleep apnoea	106
Post tuberculosis treatment infectious complications	106
Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients	106
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects	105
SARS-CoV-2 vaccines: Lights and shadows	105
Pulmonary rehabilitation in patients recovering from COVID-19	104
Tuberculosis and COVID-19 co-infection: description of the global cohort	103
Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment	101
Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort	100
History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis	99
Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success	98
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: Preliminary evidence from the AmbOx Trial	96
Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry	96
Pulmonary rehabilitation: Promising nonpharmacological approach for treating asthma?	95
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial	95
Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19	95
Severe asthma: One disease and multiple definitions	94
Correction to: When kidneys and lungs suffer together (Journal of Nephrology, (2019), 32, 5, (699-707), 10.1007/s40620-018-00563-1)	92
Post-TB disease: a new topic for investigation-and why it matters	92
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease	91
High-flow oxygen therapy during exercise training in patients with chronic obstructive pulmonary disease and chronic hypoxemia: A multicenter randomized controlled trial	91
Alpha-1 deficiency in severe asthma patients	89
A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings	89
Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)	89
Epidemic and pandemic viral infections: Impact on tuberculosis and the lung	87
An overview of Cochrane systematic reviews for pulmonary rehabilitation interventions in people with chronic obstructive pulmonary disease: a mapping synthesis	85
Time course of exercise capacity in patients recovering from covid-19-associated pneumonia	85
Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts	85
Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients	84
Effect of pulmonary rehabilitation on heart rate recovery in adult individuals with asthma or chronic obstructive pulmonary disease	83
Defining genetic risk factors for scleroderma-associated interstitial lung disease: IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease	83
Current developments and future directions in COPD	83
Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up	82
24-Month assessment of respiratory function in patients hospitalized for severe SARS-CoV-2 pneumonia: a follow-up study	82
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life	81
Management of chronic refractory cough in adults	80
Heart rate recovery in adult individuals with asthma	79
Totale	13.504

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	79.341
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	79.341

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	732	0	0	0	11	33	63	85	72	58	244	69	97
2022/2023	1.055	102	82	104	132	58	227	6	109	133	49	21	32
2023/2024	1.808	248	259	245	301	374	154	72	18	75	39	6	17
2024/2025	1.880	20	25	281	50	74	140	67	76	237	275	176	459
2025/2026	4.508	314	272	247	485	312	221	1.020	288	495	293	287	274
2026/2027	1.504	156	231	528	589	0	0	0	0	0	0	0	0
Totale													15.340